Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial

Abstract

Endometrial cancer is the most common gynaecologic malignancy in industrialised countries. Fifteen to twenty per cent of patients with presumed localised disease at primary treatment recur.¹ x 1 Morrow, C.P., Bundy, B.N., Kurman, R.J. et al. Relationship between surgical–pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1991; 40: 55–65 Google Scholar See all References ^{, 2} x 2 Abeler, V.M. and Kjorstad, K.E. Endometrial adenocarcinoma in Norway. A study of a total population. Cancer. 1991; 67: 3093–3103 Google Scholar See all References Of all patients dying from this disease, one third was initially classified as low risk for recurrence.³ x 3 Bray, F. Cancer in Norway 2008 report. Cancer Registry of Norway, Oslo; 2009 Google Scholar See all References Contrasting breast cancer,⁴ x 4 EBCTCG EBCTCG. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365: 1687–1717 Google Scholar See all References ^{, 5} x 5 Chang, H.R. Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer. Cancer. 2010; 116: 2856–2867 Google Scholar See all References improved knowledge of molecular alterations relevant for prognostication and targeting therapies in endometrial cancer⁶ x 6 Dedes, K.J., Wetterskog, D., Ashworth, A., Kaye, S.B., and Reis-Filho, J.S. Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol. 2011; 8: 261–271 Google Scholar See all References ^{, 7} x 7 Salvesen, H.B., Carter, S.L., Mannelqvist, M. et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci U S A. 2009; 106: 4834–4839 Google Scholar See all References has not been systematically incorporated to tailor therapy.⁸ x 8 Salvesen, H.B., Haldorsen, I.S., and Trovik, J. Markers for individualised therapy in endometrial carcinoma. Lancet Oncol. 2012; 13: e353–e361 Google Scholar See all References